Company Virios Therapeutics, Inc.

Equities

VIRI

US92829J1043

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.4695 ^USD	+3.01%		+7.81%	-18.35%

Feb. 29	Virios Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Jan. 22	Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid	CI

Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.

Number of employees: 4

Managers	Title	Age	Since
Gregory Duncan CEO	Chief Executive Officer	59	17-12-31
Angela Walsh DFI	Director of Finance/CFO	58	20-03-31
Ralph Grosswald COO	Chief Operating Officer	55	20-03-31
R. Gendreau CTO	Chief Tech/Sci/R&D Officer	68	12-02-27
Richard Burch BRD	Director/Board Member	67	13-12-31

Members of the board	Title	Age	Since
John Thomas BRD	Director/Board Member	70	20-12-20
Richard Whitley BRD	Director/Board Member	78	20-12-20
Gregory Duncan CEO	Chief Executive Officer	59	17-12-31
Abel de la Rosa BRD	Director/Board Member	61	20-12-20
William Pridgen FOU	Founder	63	12-02-27
Richard Burch BRD	Director/Board Member	67	13-12-31
David Keefer BRD	Director/Board Member	71	17-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	19,257,937	17,387,608 ( 90.29 %)	0	90.29 %

Name	Equities	%	Valuation
R. Huntsman 9.485 %	1,826,521	9.485 %	874 904 $
Brian Corday 4.582 %	882,400	4.582 %	422 670 $
William Pridgen 3.953 %	761,279	3.953 %	364 653 $
Ionic Ventures LLC 3.621 %	697,292	3.621 %	334 003 $
Vanguard Group, Inc. (Subfiler) 1.085 %	208,883	1.085 %	100 055 $
Renaissance Technologies LLC 1.073 %	206,697	1.073 %	99 008 $
Geode Capital Management LLC 0.9060 %	174,469	0.9060 %	83 571 $
Richard Burch 0.7669 %	147,681	0.7669 %	70 739 $
Gregory Duncan 0.2984 %	57,461	0.2984 %	27 524 $
STATE STREET CORPORATION 0.2743 %	52,828	0.2743 %	25 305 $

Virios Therapeutics, Inc.

44 Milton Avenue

30009, Alpharetta

http://www.virios.com

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.4695 USD

Average target price

2.2 USD

Spread / Average Target

+368.58%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VIRIOS THERAPEUTICS, INC.	-18.35%	9.04M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs